Crystal forms and preparation methods of isobutyric acid nucleoside compounds

A stable crystalline form of a nucleoside analog addresses drug stability and bioavailability issues, improving antiviral efficacy through controlled preparation methods.

JP2024542143AInactive Publication Date: 2024-11-13SHENZHEN ANTIV PHARMA CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024526904
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2022-11-04
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing antiviral drug development for COVID-19 focuses on key proteins like 3CLpro and RdRp, but the crystalline forms of nucleoside compounds affecting drug quality, stability, and bioavailability are not adequately addressed.

Method used

Development of a stable crystalline form III of a nucleoside analog with specific X-ray diffraction peaks, prepared through controlled solvent precipitation and pH adjustment, ensuring high solubility and chemical stability.

Benefits of technology

The crystalline form III exhibits good physical and chemical stability, high solubility, and ease of industrial production, enhancing the drug's effectiveness and bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542143000011
    Figure 2024542143000011
  • Figure 2024542143000012
    Figure 2024542143000012
  • Figure 2024542143000013
    Figure 2024542143000013
Patent Text Reader

Abstract

The present invention provides a crystalline form of isobutyric acid nucleoside compound and its preparation method, the crystalline form is III, and the X-ray powder diffraction pattern has characteristic peaks at 2θ values ​​of 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2° and 28.66±0.2°. The crystalline form III has good physical and chemical stability. The preparation method of the crystalline form has the advantages of simple operation and high reproducibility.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of medical technology and relates to a crystalline form and preparation method of isobutyric acid nucleoside compound. [Background technology]

[0002] The 2019 novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) is an enveloped, single-stranded RNA virus belonging to the βcoronavirus genus. Similar to SARS and MERS, the SARS-CoV-2 genome encodes nonstructural proteins such as 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase, and RNA-dependent RNA polymerase (RdRp), as well as structural proteins such as spike glycoprotein and accessory proteins. The surface spike protein of SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the human cell surface to infect human respiratory epithelial cells. After entering the host cell, the virus disintegrates, releasing the nucleocapsid and viral RNA into the cytoplasm. The open reading frame (ORF1a / b) at the 5' end of the viral RNA encodes a polyprotein (pp1a and pp1ab) that plays a key role in the enzymatic processing and maturation required for viral replication. PP1a and PP1ab can be cleaved by PLPro and 3CLPro to produce nonstructural proteins, including helicase and RNA-dependent RNA polymerase, which play important roles in the transcription and replication of SARS-CoV-2. Currently, these four proteins, including the surface spike glycoprotein of the coronavirus recognition receptor, and the key proteins involved in the viral replication and transcription processes, 3CLpro, PLpro, and RdRp, are very attractive targets for antiviral drug development.

[0003] The compound of formula A is a nucleoside analogue that acts on RdRp, has good oral bioavailability, and good in vitro and in vivo anti-coronavirus activity. The applicant of the present application has filed a patent application describing the use and synthesis process of the compound for treating viral infections. For details, please refer to Chinese Patent Applications No. 202111083730.9 and 202110621245.6. [ka]

[0004] Drug polymorphism is a common phenomenon in drug research and is an important factor that affects the quality of drugs. Different crystalline forms of the same drug have significantly different appearances, solubility, melting points, dissolution, bioavailability, etc., and also have different effects on stability, bioavailability, and efficacy. Therefore, drug polymorphism must be considered comprehensively in drug research.

[0005] The present inventors have conducted related studies on the crystalline form of the compound of formula A and found that the crystalline form has the advantages of simple preparation process, good stability and high solubility. Summary of the Invention

[0006] The present invention mainly relates to the crystalline form III of the compound of formula A. The partially crystalline form provided herein has the advantages of a simple preparation process, high reproducibility conducive to industrial production, and good physical and chemical stability suitable for formulation.

[0007] In other aspects, the present invention provides methods for preparing, compositions and uses of crystalline Form III of the compound of formula A.

[0008] In a first aspect, the present invention provides a crystalline form of a compound of formula A. [ka] A crystalline form of the compound of formula A.

[0009] In some embodiments, the X-ray powder diffraction pattern of crystalline Form III of the compound of formula A has characteristic peaks at 2θ values ​​of 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2°, and 28.66±0.2°.

[0010] In some embodiments, the X-ray powder diffraction pattern of crystalline Form III of the compound of Formula A has characteristic peaks at 2θ values ​​of 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2°, 28.66±0.2°, 10.52±0.2°, 11.80±0.2°, and 14.04±0.2°.

[0011] In some embodiments, the X-ray powder diffraction pattern of the crystalline Form III of the compound of formula A is 8.475, 10.523, 11.808, 14.043, 15.331, 16.878, 17.470, 20.293, 21.106, 22.131, 23.733, 24.074, 24.545, 24.915, 25.688, 26.147 , 26.528, 26.778, 27.526, 28.079, 28.669, 30.126, 30.783, 31.044, 31.689, 32.110, 32.793, 33.304, 34.868, 35.431, 35.746, 36.494, 37.007, and 37.887, and have characteristic peaks at 2θ ± 0.2° values.

[0012] In some embodiments, the X-ray powder diffraction pattern of crystalline Form III of the compound of Formula A is substantially as shown in Figure 1. The differential scanning calorimetry (DSC) curve of crystalline Form III of the compound of Formula A is substantially as shown in Figure 4. The thermogravimetric analysis (TGA) curve is substantially as shown in Figure 5. In some embodiments, crystalline Form III is essentially pure, i.e., crystalline Form III is substantially free of one or more other crystalline forms.

[0013] In a second aspect, the present invention provides a method for preparing crystalline Form III of the compound of formula A described in the first aspect.

[0014] The method for preparing crystalline form III of compound of formula A according to the first aspect comprises the steps of: The process involves dissolving the compound of formula A in water at room temperature, cooling to -5.0°C to 5.0°C, adding an ester solvent, precipitating the solid, filtering, and evaporating the solvent in the filter cake to obtain a crystalline form.

[0015] For every 100 grams of compound of formula A, the amount of water used may be 200 ml to 500 ml, and the amount of ester solvent used may be 100 ml to 200 ml. In some embodiments, for every gram of compound of formula A, the amount of water used may be 50 to 300 ml, and the amount of ester solvent used may be 50 to 200 ml. In some embodiments, the ester solvent is selected from methyl formate, ethyl acetate, isobutyl acetate, and the like.

[0016] In some embodiments, the method for preparing crystalline form III includes adding water, organic acid and INT-1 to a reaction vessel at a temperature of 20°C to 30°C, stirring at room temperature for more than 24 hours, sampling to detect the reaction end point (the reaction is considered to be completed when the peak area of ​​INT-2 is less than 0.5%), cooling to -5.0°C to 5.0°C, adding ester solvent, adjusting the pH value to 7 to 8 by adding alkaline aqueous solution, stirring for more than 1 hour, filtering, and washing the filter cake with water. [ka]

[0017] In some embodiments, the organic acid is formic acid or acetic acid, the volume ratio of the organic acid to water is 3:1 to 1:1, preferably about 2:1, and the ester solvent is selected from methyl formate, ethyl acetate, or isobutyl acetate, etc.

[0018] In a third aspect, the present invention provides a composition.

[0019] The composition comprises the crystalline form of the first aspect and a pharma- ceutically acceptable adjuvant.

[0020] Calculated by mass, the crystalline form represents at least 0.05% to 95% of the total mass of the composition.

[0021] In a fourth aspect, the present invention provides the use of said crystalline form or said composition.

[0022] The composition includes a Chinese herbal medicine component and / or a Western medicine component, the Western medicine component including apilimod, R82913, DS-6930, ONO 5334, remdesivir, oseltamivir phosphate, tetrandrine, clofazimine, astemizole, recombinant human angiotensin-converting enzyme 2, or favipiravir, and / or at least one pharmaceutically acceptable salt thereof.

[0023] The use of the crystalline form of the first aspect or the composition of the third aspect for the manufacture of a product for preventing, alleviating and / or treating a viral infection or its replication or proliferation, and its cytopathic effects.

[0024] Use of the crystalline form of the first aspect or the composition of the third aspect for the manufacture of a product for preventing, alleviating and / or treating the replication or proliferation of a coronavirus infection or its homologous variants, and its cytopathic effects.

[0025] Coronaviruses include MHV-A59, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2, mouse hepatitis virus, feline infectious peritonitis virus, canine coronavirus, bovine coronavirus, avian infectious bronchitis virus, or porcine coronavirus.

[0026] Beneficial effects Compared with the prior art, the present invention has the following technical advantages: the crystalline form III of compound of formula A disclosed herein has good physical and chemical stability, is convenient for storage, meets the requirements of drug stability, and also has good solubility and high bioavailability, and the preparation process is simple and favorable for industrial production.

[0027] definition Unless otherwise stated, the following terms and phrases used herein shall have the following meanings:

[0028] "A compound of the invention" refers to a compound of formula A, or a pharma- ceutically acceptable salt, tautomer, polymorph, isomer, or solvate thereof. Similarly, "a compound of formula A" refers to a compound, or a pharma- ceutically acceptable salt, tautomer, polymorph, isomer, or solvate thereof.

[0029] In the present invention, "compound A" and "compound of formula A" refer to the same compound.

[0030] The term "crystalline form" refers to a crystal structure formed by different arrangements of molecules within the lattice spaces through intra- or intermolecular bonds.

[0031] The term "essentially pure" refers to a crystalline form that is substantially free of one or more other crystalline forms, having a purity of at least 60%, or at least 70%, or at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 98%, or at least 99%, and in addition to the predominant crystalline form, small amounts of other crystalline forms may be mixed therein. The weight percentage of other crystalline forms is less than 20%, or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.

[0032] The term "substantially free of one or more other crystalline forms" refers to the percentage of other crystalline forms by total weight being less than 20%, or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.

[0033] The term "substantially as shown in the figure" means that at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of the characteristic peaks present in an X-ray powder diffraction pattern are present in a given X-ray powder diffraction pattern.

[0034] In the context of the present invention, all numerical values ​​disclosed herein are approximate, regardless of whether words such as "approximately" or "about" are used. Each numerical value may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15%, or 20%. Whenever a numerical value having a value N is disclosed, any numerical value having a value N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15%, or N+ / -20% is expressly disclosed, where "+ / -" means plus or minus. Whenever a numerical range with a lower limit RL and an upper limit RU is disclosed, any numerical value falling within the range is specifically disclosed. In particular, the following numerical values ​​within the range are specifically disclosed, where R=RL+K*(RU-RL), where K is a variable from 1% to 100% in 1% increments. For example, 1%, 2%, 3%, 4%, 5%... 50%, 51%, 52%... 95%, 96%, 97%, 98%, 99%, or 100%. Additionally, any numerical range defined by two R numbers as defined above is specifically disclosed.

[0035] In the context of this invention, all 2θ values ​​in X-ray powder diffraction patterns are in degrees (°).

[0036] "V / V" stands for volume ratio. IC 50 represents the half maximal inhibitory concentration.

[0037] "wt%" refers to the mass percentage of a component based on the total mass of the mixture.

[0038] In the present invention, "room temperature" refers to an ambient temperature ranging from about 10° C. to about 40° C. In some embodiments, "room temperature" refers to a temperature ranging from about 20° C. to about 30° C. In other embodiments, "room temperature" refers to a temperature ranging from about 25° C. to about 30° C. In some other embodiments, "room temperature" refers to 10° C., 15° C., 20° C., 25° C., 30° C., 35° C., 40° C., etc.

[0039] As used herein, unless otherwise indicated, the term "treating" means reversing or alleviating the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition, or inhibiting the progression of said disorder or condition, or one or more symptoms of such disorder or condition, or preventing said disorder or condition, or one or more symptoms of such disorder or condition. As used herein, the term "treatment" refers to the act of treating, as "treating" is defined immediately above.

[0040] Equipment parameters Unless otherwise specified in the parameter descriptions, all analyses below are carried out at room temperature.

[0041] X-ray powder diffraction studies X-ray powder diffraction patterns were collected on a PANalytical Empyrean X-ray diffractometer in the Netherlands equipped with a transmission-reflection sample stage with an automatic 3*15 zero-background sample holder. The radiation source used was (Cu, kα, Kα1 (Å): 1.540598, Kα2 (Å): 1.544426; Kα2 / Kα1 intensity ratio: 0.50), the voltage was set at 45 KV, and the current was set at 40 mA. The beam divergence of the X-rays, i.e., the effective size of the X-ray confinement on the sample, was 6.6 mm. A θ-θ continuous scanning mode was adopted, obtaining an effective 2θ range of 3°-40°. An appropriate amount of sample was placed in the circular groove position of the zero-background sample rack under environmental conditions (approximately 18°C-32°C), the sample was lightly pressed with a clean glass slide to make it a flat surface, and the zero-background sample rack was fixed. Conventional X-ray powder diffraction patterns were obtained by scanning the samples in the range 3° to 40° 2θ ± 0.2° with a scan step of 0.013°. The software used for data collection was Data Collector, and the data were analyzed and presented using Data Viewer and HighScore Plus.

[0042] High performance liquid chromatography (HPLC) detection of crystalline forms The instrument used for the liquid chromatography analysis was an Agilent HPLC 1260 series used for the analysis of the solid state stability of the samples. [Brief description of the drawings]

[0043] [Figure 1] FIG. 2 shows the X-ray powder diffraction pattern of crystalline form III prepared in an example of the present invention. [Diagram 2] FIG. 2 shows X-ray powder diffraction patterns of crystalline form III prepared in an example of the present invention stored under various conditions. [Diagram 3] FIG. 2 shows X-ray powder diffraction patterns of crystalline form III prepared in an example of the present invention dissolved in various solvents. [Figure 4] FIG. 2 is a differential scanning calorimetry (DSC) curve of crystalline form III prepared in an example of the present invention. [Diagram 5] FIG. 2 is a diagram showing a thermogravimetric analysis curve (TGA) of the crystalline form III prepared in an example of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] In order to make those skilled in the art better understand the technical solutions of the present invention, non-limiting embodiments are further disclosed to further illustrate the present invention.

[0045] The reagents used in the present invention are either commercially available or can be prepared by the methods described herein.

[0046] In the present invention, μM means micromoles per liter, mmol means millimoles, equiv means equivalent weight and aw means water activity.

[0047] Example 1. Synthesis of (3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile (Compound 5) [ka] 5.62g of compound 69-0 was dissolved in 30mL of acetone, 11.50mL of 2,2-dimethoxypropane and 1.34mL of 98% sulfuric acid were added, stirred at 45°C for 30 minutes, cooled to room temperature, and the organic solvent was removed by rotary evaporation. The mixture was extracted three times with 100mL of ethyl acetate and 100mL of saturated sodium bicarbonate solution, and the ethyl acetate layers were combined, dried over anhydrous sodium sulfate, and filtered to remove sodium sulfate. The organic solvent was removed by rotary evaporation, and the product was purified by column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 1 / 2) to obtain 6.20g of compound 5 (white solid, 97% yield). The hydrogen spectrum of the obtained compound 5 was measured, and the following results were obtained. Hydrogen spectrum: 1H NMR(400MHz,Chloroform-d)δ7.95(s,1H),7.11(d,J=4.7Hz,1H),6.69(dd,J=4.8,2.4Hz,1H),5.77(s,2H),5.42(d,J=6.6Hz,1H),5.2 4(dd,J=6.6,2.4Hz,1H),4.67(q,J=1.9Hz,1H),3.99(dd,J=12.5,1.9Hz,1H),3.84(dd,J=12.5,1.7Hz,1H),1.81(s,3H),1.40(s,3H).

[0048] Example 2. Synthesis of methyl ((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)isobutyrate (compound INT-1) [ka] 1.50 g of compound 5 was dissolved in 15 mL of dichloromethane, 0.42 mL of isobutyric acid and 55.40 mg of 4-dimethylaminopyridine were added, and the mixture was stirred for 10 minutes, after which 1.02 g of dicyclohexylcarbodiimide was added and the mixture was stirred at room temperature for 24 hours. The mixture was purified by column chromatography (eluent: petroleum ether / ethyl acetate (v / v)=1 / 1) to obtain 1.71 g of compound INT-1 (white solid, yield 94%). The hydrogen spectrum of the obtained compound INT-1 was measured, and the following results were obtained. Hydrogen spectrum: 1 H NMR(400MHz,CDCl3,ZQF-RD01-2)δ(ppm):7.99(s,1H),6.99(d,J=4.6Hz,1H),6.62(d,J=4.6Hz,1H),5.72(br,2H),5.49(d,J=6.8Hz,1H),4.93-4.90 (dd,J=6.8Hz,4.3Hz,1H),4.61-4.58(q,J=4.4Hz,1H),4.44-4.26(m,2H), 2.61-2.50(m,1H),1.77(s,3H),1.42(s,3H),1.17-1.14(q,J=3.8Hz,6H). Carbon spectrum:13 C NMR(100MHz,CDCl3,ZQF-RD01-2)δ(ppm):176.7,155.2,147.3,123.5,117.2,11 6.7,115.6,112.6,100.0,83.8,83.0,82.0,81.4,63.1,33.8,26.4,25.6,18.9.

[0049] Example 3. Synthesis of methyl ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)isobutyrate (Compound A) [ka] Water (310 mL) was added to the reaction vessel at a temperature of 20-30 °C, formic acid (620 mL) was added, then INT-1 (1.0 equiv., 93 g) was added, the mixture was stirred at room temperature for more than 24 h, a sample was taken to detect the reaction end point (when the peak area of ​​INT-1 is less than 0.5%, the reaction is considered to be completed), the mixture was cooled to -5.0 °C, ethyl acetate (186 mL) was added, and the pH was adjusted to 7-8 by adding 50% aqueous sodium carbonate solution, the mixture was stirred for more than 1 h, filtered, and the filter cake was washed with water (288 mL × 3) to obtain compound A.

[0050] Example 4: Characterization and detection of crystalline forms X-ray powder diffraction, differential scanning calorimetry, and thermogravimetry were performed on the compound prepared in Example 1. The results are shown in Figures 1 to 3. A new crystalline form of Compound A, designated as crystalline form III, was obtained.

[0051] Example 5: Dynamic water vapor sorption detection of crystalline form III The results of the dynamic water vapor adsorption test showed that the crystalline form III had no hygroscopicity. Under the conditions of 80% RH and 25°C, the weight increase was less than 0.2%, and the crystalline form did not change after the test, which demonstrated that the crystalline form stability of the crystalline form III was good.

[0052] Example 6: Milling experiment of crystalline form III Form III was manually ground with a mortar and pestle for 5 minutes and the XRPD of the ground solid was examined. After 5 minutes of grinding, the crystal structure did not change, indicating good physical stability of Form III.

[0053] Example 7: Solid State Stability Studies A certain amount of crystalline form III of compound A was placed under conditions of 40°C / 75%RH (open) and 60°C (closed) for one week, and the sample was examined by XRPD and HPLC. The results are shown in the table below. Crystalline form III was physically and chemically stable for 14 days under the two accelerated conditions. [Table 1]

[0054] Example 8: Solubility test results The results of the solubility test of crystalline form III of Compound A in biological media (SGF, FaSSIF, and FeSSIF) and water at 37°C are shown in the table below. Crystalline form III has the highest solubility in SGF (>7mg / mL). The solubilities in pure water, FeSSIF, and FaSSIF were all above 1mg / mL. There was no significant change in the pH of the solutions after the solubility test. [Table 2]

[0055] Although the method of the present invention has been described through the preferred embodiments, it is obvious that a person skilled in the art can appropriately make any modifications, changes, or combinations thereof to implement and apply the present invention without departing from the content, spirit and scope of the present invention. Those skilled in the art can learn from the present invention and appropriately improve the process parameters. In particular, it should be noted that all similar replacements and modifications are obvious to those skilled in the art and are considered to be included in the present invention.

Claims

1. A crystalline form of a compound of formula A, 【Chemistry 1】 A crystalline form of the compound of formula A, wherein the X-ray powder diffraction pattern of crystalline Form III is characterized by having characteristic peaks at 2θ values ​​of 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2° and 28.66±0.2°.

2. 2. The crystalline form of claim 1, wherein the X-ray powder diffraction pattern of crystalline Form III has characteristic peaks at 2θ values ​​of 8.47±0.2°, 16.87±0.2°, 17.47±0.2°, 22.13±0.2°, 28.66±0.2°, 10.52±0.2°, 11.80±0.2°, and 14.04±0.2°.

3. The X-ray powder diffraction pattern of crystalline Form III is: 8.475, 10.523, 11.808, 14.043, 15.331, 16.878, 17.470, 20.293, 21.106, 22.131, 23.733, 24.074, 24.545, 24.915, 25.688, 26.147, 26.528, 26.778 2. The crystalline form of claim 1, having characteristic peaks at 2θ±0.2° values ​​of 27.526, 28.079, 28.669, 30.126, 30.783, 31.044, 31.689, 32.110, 32.793, 33.304, 34.868, 35.431, 35.746, 36.494, 37.007, and 37.

887.

4. 2. The crystalline form of claim 1, wherein the X-ray powder diffraction pattern of crystalline Form III is substantially as shown in FIG.

5. A method for preparing crystalline form III according to any one of claims 1 to 4, comprising: adding water, an organic acid and INT-1 to a reaction vessel at a temperature of 20°C to 30°C; stirring at room temperature for at least 24 hours; cooling to -5.0°C to 5.0°C after the reaction is completed; adding an ester solvent; adjusting the pH value to 7-8 by adding an alkaline aqueous solution; stirring for at least 1 hour; filtering; washing the filter cake with water; and drying. 【Chemistry 2】

6. 6. The method according to claim 5, wherein the organic acid is formic acid or acetic acid, and the volume ratio of the organic acid to water is 3:1 to 1:

1.

7. 6. The method of claim 5, wherein the ester solvent is selected from one or more of methyl formate, ethyl acetate, or isobutyl acetate.

8. A composition comprising the crystalline form of any one of claims 1 to 4 and a pharma- ceutically acceptable adjuvant.

9. Use of the crystalline form of any one of claims 1 to 4 or the composition of claim 8 for the manufacture of a product for preventing, alleviating and / or treating the replication or proliferation of a coronavirus infection or its homologous mutants, and its cytopathic effects.

10. The use according to claim 9, wherein the coronavirus comprises MHV-A59, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2, mouse hepatitis virus, feline infectious peritonitis virus, canine coronavirus, bovine coronavirus, avian infectious bronchitis virus, or porcine coronavirus.

Citation Information

Patent Citations

  • Application of nucleoside analogue or combined preparation containing nucleoside analogue in virus resistance

    CN112778310A

  • Nucleoside compound and application thereof in treatment of feline infectious peritonitis

    CN113185519A

  • Compounds and methods for treatment of viral infections

    WO2022047065A2